Literature DB >> 23399487

Comparison of methohexital and etomidate as anesthetic agents for electroconvulsive therapy in affective and psychotic disorders.

H Janouschek1, T Nickl-Jockschat, M Haeck, B Gillmann, M Grözinger.   

Abstract

BACKGROUND: ECT is a well-established treatment for severe depression. The available data on psychosis are limited, but reliable. Its therapeutic potential relies on the induction of a generalized seizure. Besides other narcotics, methohexital and etomidate are used for general anesthesia in ECT. Since prolonged seizures have been reported following the use of etomidate, it can be deduced that the substances might differ in their anticonvulsant properties, resulting in a lower increase in stimulus intensity during the course of treatment under etomidate. Besides this hypothesis, we aimed to investigate the differential effects of etomidate and methohexital on clinical features, ECT parameters and side effects of the treatment.
METHODS: We performed a retrospective analysis of treatment data of patients with affective and psychotic diagnosis who received general anesthesia for ECT either with etomidate or with methohexital.
RESULTS: ECT with etomidate and methohexital was equally effective. During the course of therapies the administered electric charge increased significantly and equally in both treatment groups. In the methohexital group, but not in the etomidate group, electroencephalographic seizure duration had a declining trend during the course of therapies. We observed more side effects during and immediately after ECT in the methohexital group than in the etomidate group. LIMITATIONS: The limitations of this study are that the patients received various psychotropic co-medications, which influence ictal parameters differently, and, secondly, the study is based on a retrospective analysis.
CONCLUSION: The results of our analysis suggest that etomidate and methohexital affect ictal parameters to different extents. Longer seizure duration and fewer side effects are in favor of etomidate.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23399487     DOI: 10.1016/j.jpsychires.2012.12.019

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  6 in total

1.  Impact of the anesthetic agents ketamine, etomidate, thiopental, and propofol on seizure parameters and seizure quality in electroconvulsive therapy: a retrospective study.

Authors:  Carolin Hoyer; Laura Kranaster; Christoph Janke; Alexander Sartorius
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-07-09       Impact factor: 5.270

2.  Brief vs. ultrabrief pulse ECT: focus on seizure quality.

Authors:  Isabelle Brunner; Michael Grözinger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-07-18       Impact factor: 5.270

3.  The influence of anaesthetic choice on seizure duration of electroconvulsive therapy; etomidate versus methohexital.

Authors:  Laila Chomrikh; Mustafa Ahmadi; T Martijn Kuijper; Joris J B van der Vlugt; Seppe J H A Koopman
Journal:  BMC Anesthesiol       Date:  2022-07-05       Impact factor: 2.376

4.  Are morphological changes necessary to mediate the therapeutic effects of electroconvulsive therapy?

Authors:  Thomas Nickl-Jockschat; Nicola Palomero Gallagher; Vinod Kumar; Felix Hoffstaedter; Elisabeth Brügmann; Ute Habel; Simon B Eickhoff; Michael Grözinger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-11       Impact factor: 5.270

5.  Anesthetic agent etiomidate induces apoptosis in N2a brain tumor cell line.

Authors:  Hong-Tao Chen; Jun Zhou; You-Ling Fan; Chun-Liang Lei; Bao-Jin Li; Li-Xin Fan; Li Xu; Ming Xu; Xiu-Qin Hu; Zhi-Ying Yu
Journal:  Mol Med Rep       Date:  2018-07-19       Impact factor: 2.952

6.  Medication management during electroconvulsant therapy.

Authors:  Monica Zolezzi
Journal:  Neuropsychiatr Dis Treat       Date:  2016-04-19       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.